Shailendra Singh (Shelly) is Chief Operating Officer of MnM and a member of its board. He focuses on global sales and client services functions, as well as commercial optimization at MarketsandMarkets. He has years of expe¬rience in global delivery and outsourcing sector in the IT/ Consulting/Analytics/Big Data sectors. Prior to MnM, he was leading the global sales, client services and commercial ef¬fectiveness functions for Mu Sigma, a unicorn company and a leading global provider of Decision Sciences and Big Data analytics solutions.
Sewell group research is focused around T-cell ligands and the receptors that recognise them during infection, autoimmune disease, transplant rejection and cancer immunotherapy. The alpha-beta TCR can exploit the MHC class I presentation pathway to target any cell based on its expression of any protein in vivo, thereby accessing a far greater range of targets than are accessible to monoclonal antibodies. Our newer studies indicate that alpha-beta and gamma-delta TCRs can target neoplasms by other, novel mechanisms. We aim to exploit these findings to generate new, broad-spectrum cancer therapeutics.
Scott K. Durum PhD trained at Oak Ridge, National Jewish Denver and Yale before coming to the National Cancer Institute, National Institutes of Health where he is chief of the Section of Cytokines and Immunity. His lab has studied the role of cytokines in the immune system, with a long interest in the IL-7 pathway which is essential for T lymphocyte development and survival. His lab together with collaborators found gain-of-function mutations in the IL-7 receptor that drive acute lymphoblastic leukemia, the most common cancer in children. They are currently studying the mechanism of leukemogenesis and developing therapeutics to target the pathway. He also plays in NIH’s band, the Affordable Rock n Roll Act.